Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has been given a $18.00 target price by equities researchers at HC Wainwright in a report issued on Wednesday, August 9th. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 323.53% from the stock’s current price.
Several other analysts have also commented on ALDX. Zacks Investment Research lowered shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 30th. Stifel Nicolaus restated a “buy” rating and set a $16.00 price target on shares of Aldeyra Therapeutics in a research report on Wednesday, May 31st. Finally, Canaccord Genuity set a $12.00 target price on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 14th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Aldeyra Therapeutics currently has an average rating of “Buy” and an average price target of $14.15.
Aldeyra Therapeutics (NASDAQ:ALDX) opened at 4.25 on Wednesday. The stock’s market cap is $26.54 million. Aldeyra Therapeutics has a 1-year low of $3.80 and a 1-year high of $8.19. The company’s 50 day moving average is $4.65 and its 200-day moving average is $4.74.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.com-unik.info/2017/08/19/hc-wainwright-analysts-give-aldeyra-therapeutics-inc-nasdaqaldx-a-18-00-price-target-updated.html.
In related news, major shareholder Life Sciences Maste Perceptive bought 296,007 shares of the company’s stock in a transaction dated Friday, June 30th. The shares were acquired at an average price of $4.60 per share, for a total transaction of $1,361,632.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 28.40% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Aldeyra Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after buying an additional 9,407 shares in the last quarter. Virtu KCG Holdings LLC acquired a new position in Aldeyra Therapeutics during the second quarter valued at $104,000. Renaissance Technologies LLC acquired a new position in Aldeyra Therapeutics during the first quarter valued at $132,000. Hikari Power Ltd acquired a new position in Aldeyra Therapeutics during the first quarter valued at $188,000. Finally, Sabby Management LLC acquired a new position in Aldeyra Therapeutics during the first quarter valued at $898,000. 58.20% of the stock is currently owned by hedge funds and other institutional investors.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
What are top analysts saying about Aldeyra Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aldeyra Therapeutics Inc. and related companies.